Cargando…

Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia

BACKGROUND: Extramedullary involvement of B-cell Acute Lymphoblastic Leukemia (EM-ALL) is a rare occurrence, characterized by dismal outcome and the absence of a defined and shared therapeutic approach. In the landscape of innovative compounds, inotuzumab ozogamicin (IO) is a promising drug, whose m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bertamini, Luca, Nanni, Jacopo, Marconi, Giovanni, Abbenante, Mariachiara, Robustelli, Valentina, Bacci, Francesco, Matti, Antonella, Paolini, Stefania, Sartor, Chiara, Monaco, Silvia Lo, Fontana, Maria Chiara, De Polo, Stefano, Cavo, Michele, Curti, Antonio, Martinelli, Giovanni, Papayannidis, Cristina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6238377/ https://www.ncbi.nlm.nih.gov/pubmed/30442119 http://dx.doi.org/10.1186/s12885-018-5026-x

Ejemplares similares

Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia
por: Ravaioli, Federico, et al.
Publicado: (2021)

Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin
por: Kayser, Sabine, et al.
Publicado: (2022)

Inotuzumab ozogamicin for acute lymphoblastic leukaemia
Publicado: (2019)

Acute Myeloid Leukemia Mutations: Therapeutic Implications
por: Papayannidis, Cristina, et al.
Publicado: (2019)

Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia
por: Savoy, J. Michael, et al.
Publicado: (2018)

Primary refractory B-cell lymphoblastic leukemia with extramedullary disease – a distinctive response to blinatumomab and inotuzumab ozogamicin
por: Silva, Wellington Fernandes da, et al.
Publicado: (2019)

The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report
por: De Benedittis, Caterina, et al.
Publicado: (2017)

P375: INOTUZUMB OZOGAMICIN PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RELAPSED OR REFRACTORY ACUTE B-LYMPHOBLASTIC LEUKEMIA
por: Kayser, Sabine, et al.
Publicado: (2023)

Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study
por: Fracchiolla, Nicola Stefano, et al.
Publicado: (2023)

A Case Report of Acute Myeloid Leukemia and Neurofibromatosis 1
por: Sartor, Chiara, et al.
Publicado: (2013)

Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia
por: Stock, Wendy, et al.
Publicado: (2020)

Posterior Reversible Encephalopathy Syndrome in a B-Cell Acute Lymphoblastic Leukemia Young Adult Patient Treated with a Pediatric-Like Chemotherapeutic Schedule
por: Papayannidis, Cristina, et al.
Publicado: (2014)

Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
por: Bhojwani, Deepa, et al.
Publicado: (2018)

Inotuzumab Ozogamicin in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
por: Williams, Sherry, et al.
Publicado: (2018)

Primary ovarian insufficiency secondary to chemotherapy with inotuzumab ozogamicin and other agents
por: Maristany, Sumiko, et al.
Publicado: (2022)

The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study
por: Marconi, Giovanni, et al.
Publicado: (2023)

Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia
por: Rorà, Andrea Ghelli Luserna Di, et al.
Publicado: (2016)

P558: ABSOLUTE LYMPHOCYTE COUNT IS AN INDEPENDENT SURVIVAL PREDICTOR COMPARED TO MINIMAL RESIDUAL DISEASE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE CHEMOTHERAPY
por: Cristiano, Gianluca, et al.
Publicado: (2023)

Management of important adverse events associated with inotuzumab ozogamicin: expert panel review
por: Kebriaei, Partow, et al.
Publicado: (2018)

Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia
por: Uy, Natalie, et al.
Publicado: (2018)

Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma
por: Aujla, Amandeep, et al.
Publicado: (2019)

Correction: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
por: Bhojwani, Deepa, et al.
Publicado: (2019)

Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden
por: DeAngelo, Daniel J., et al.
Publicado: (2020)

Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients
por: Zuffa, Elisa, et al.
Publicado: (2015)

Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia
por: Ghelli Luserna Di Rorà, Andrea, et al.
Publicado: (2018)

Role of the Advanced Practice Provider in Clinical Trials: Contributions to the Management of Patients Receiving Inotuzumab Ozogamicin
por: Welch, Mary Alma, et al.
Publicado: (2017)

Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma
por: Garrett, May, et al.
Publicado: (2019)

Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
por: Proskorovsky, Irina, et al.
Publicado: (2019)

Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient?
por: Fingrut, Warren, et al.
Publicado: (2020)

Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations
por: Rubinstein, Jeremy D., et al.
Publicado: (2023)

Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53
por: Tirrò, Elena, et al.
Publicado: (2019)

Recurrent Gastrointestinal Hemorrhage in Treatment with Dasatinib in a Patient Showing SMAD4 Mutation with Acute Lymphoblastic Leukemia Philadelphia Positive and Juvenile Polyposis Hereditary Hemorrhagic Telangiectasia Syndrome
por: Sartor, Chiara, et al.
Publicado: (2013)

Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment
por: Marks, David I., et al.
Publicado: (2019)

Inotuzumab ozogamicin and blinatumomab sequential therapy for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia
por: Ueda, Tomoaki, et al.
Publicado: (2022)

Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents
por: Papayannidis, Cristina, et al.
Publicado: (2022)

Inotuzumab Ozogamicin Murine Analog–Mediated B-Cell Depletion Reduces Anti-islet Allo- and Autoimmune Responses
por: Carvello, Michele, et al.
Publicado: (2012)

Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
por: Song, Jinlin, et al.
Publicado: (2019)

Defibrotide Prophylaxis of Sinusoidal Obstruction Syndrome in Adults Treated With Inotuzumab Ozogamicin Prior to Hematopoietic Stem Cell Transplantation
por: Giglio, Fabio, et al.
Publicado: (2022)

PB1731: INOTUZUMAB OZOGAMICIN IN LYMPHOID B-CELL MALIGNANCY：A SINGLE CENTER ANALYSIS IN THE REAL WORLD
por: LV, Mengnan, et al.
Publicado: (2023)

Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia
por: Bruno, Samantha, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kr6krfhql5odpmmelbei094t0c